Routine board appointment and departure — no immediate trading catalyst. Monitor for upcoming clinical trial readouts, financing events, or pipeline updates that could drive sentiment.
Price Chart
Executive Summary
FibroBiologics announced the departure of board member Matt Link and the appointment of Kathleen (Kate) Rubins, Ph.D., a retired NASA astronaut and microbiologist, to its Board of Directors. The board change is routine and carries no financial or operational implications for the company's clinical-stage pipeline.
Key Facts
- Matt Link resigned from the Board effective July 2, 2026, with no stated reason.
- Kathleen Rubins appointed as Class III director effective July 8, 2026, serving until the 2029 annual meeting.
- Dr. Rubins also appointed to the Audit, Compensation, and Governance and Nominating Committees.
- Dr. Rubins served on the company's Scientific Advisory Board since 2022 and brings NASA/space medicine expertise.
- Compensation under standard non-employee director policy; standard indemnification agreement entered.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- No material risk from this filing; the small market cap ($4M) amplifies sensitivity to any future negative news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-299290 |
| Document: fblg-ex99_1.htm | 0001193125-26-299290 |
| Document: 0001193125-26-299290-index-headers.html | 0001193125-26-299290 |
| Document: 0001193125-26-299290-index.html | 0001193125-26-299290 |
| Document: 0001193125-26-299290.txt | 0001193125-26-299290 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers